Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04422431 · ClinicalTrials.gov registry record · Phase 2
Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT04422431 is a Phase 2 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT04422431, a Phase 2 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The main objective of the study is to evaluate the change in liver copper (Cu) concentration following 48 weeks of treatment with ALXN1840 in adult participants with Wilson Disease (WD) who have been previously treated for at least 1 year with standard of care (that is, trientine, penicillamine, or zinc). In the Treatment Period, efficacy and safety of ALXN1840 will be assessed at Week 48.
Interventions
- DRUG Bis-Choline Tetrathiomolybdate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2023-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04422431
The ClinicalTrials.gov registry entry for NCT04422431 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bis-Choline Tetrathiomolybdate is the first listed.
NCT04422431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04422431 about?
NCT04422431 is a clinical study titled "Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840". The main objective of the study is to evaluate the change in liver copper (Cu) concentration following 48 weeks of treatment with ALXN1840 in adult participants with Wilson Disease (WD) who have been previously treated for at least 1 year with standard of care (that is, trientine, penicillamine, or ...
What is the current status of trial NCT04422431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2020-12-02. Estimated completion is 2023-05-17.
What interventions are being tested in trial NCT04422431?
The interventions under investigation include: Bis-Choline Tetrathiomolybdate (DRUG).
Who is sponsoring clinical trial NCT04422431?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.